MediXall Group Statistics
Total Valuation
MediXall Group has a market cap or net worth of 752,947. The enterprise value is 4.40 million.
| Market Cap | 752,947 |
| Enterprise Value | 4.40M |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediXall Group has 209.15 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 209.15M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.38% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.90 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.84 |
| EV / Sales | 18.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.70 |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.24 |
| Interest Coverage | -9.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -356.49% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 13,833 |
| Profits Per Employee | -306,164 |
| Employee Count | 17 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.43% in the last 52 weeks. The beta is 32.24, so MediXall Group's price volatility has been higher than the market average.
| Beta (5Y) | 32.24 |
| 52-Week Price Change | +71.43% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 41.05 |
| Average Volume (20 Days) | 12,351 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, MediXall Group had revenue of 235,168 and -5.20 million in losses. Loss per share was -0.04.
| Revenue | 235,168 |
| Gross Profit | -1.21M |
| Operating Income | -4.21M |
| Pretax Income | -4.89M |
| Net Income | -5.20M |
| EBITDA | -4.17M |
| EBIT | -4.21M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 9,667 in cash and 3.65 million in debt, giving a net cash position of -3.64 million or -0.02 per share.
| Cash & Cash Equivalents | 9,667 |
| Total Debt | 3.65M |
| Net Cash | -3.64M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -5.25M |
| Book Value Per Share | -0.04 |
| Working Capital | -5.69M |
Cash Flow
In the last 12 months, operating cash flow was -1.63 million and capital expenditures -1,379, giving a free cash flow of -1.63 million.
| Operating Cash Flow | -1.63M |
| Capital Expenditures | -1,379 |
| Free Cash Flow | -1.63M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,790.26% |
| Pretax Margin | -2,079.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MediXall Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.24% |
| Shareholder Yield | -9.24% |
| Earnings Yield | -1,163.33% |
| FCF Yield | -216.19% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediXall Group has an Altman Z-Score of -149.24. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -149.24 |
| Piotroski F-Score | n/a |